PharmaTell’s Post

Great update from PharmaTell's #EyesOnPharma blog; the highlights: ➡ Sanofi is negotiating to sell a 50% stake in its consumer health company, Opella, to Clayton, Dubilier & Rice for €16 billion. The deal is expected to close in mid-2025. ➡ Regeneron faces challenges as Amgen prepares to launch a #biosimilar to #Eylea, affecting its exclusivity and revenue. ➡ Pfizer is under pressure from activist investor Starboard Value to improve R&D and M&A outcomes. ➡ Novo Nordisk's oral GLP-1 drug #Rybelsus showed a 14% reduction in cardiovascular risks in a recent study. Novo plans to submit Rybelsus for cardiovascular outcomes approvals in the United States and Europe at the beginning of the coming year. Rybelsus, FDA-approved in 2019, earned $1.6 billion in the first half of 2024, compared to $3.05 billion for #Wegovy and $8.25 billion for #Ozempic.

🚨𝐒𝐚𝐧𝐨𝐟𝐢 𝐈𝐧𝐯𝐞𝐬𝐭𝐬 €𝟒𝟎𝐌 𝐢𝐧 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧 🚨 Sanofi has announced a €40 million upgrade to its facility in Tours, France, to boost the production of transplant and diabetes medications. This investment aligns with its strategy to enhance biomanufacturing capabilities and ensure a reliable supply of critical medicines globally. Find out what future of Biologics Manufacturing holds at the Biologics Manufacturing Germany Conference: 📅 Biologics Manufacturing Germany, 18-19 February, Munich ✉️ Reach out to learn more: matt.lockwood@imapac.com #Imapac #ImagineYourImpact #Sanofi #Biomanufacturing #Biopharma #EuropeanBiomanufacturing

Chronic Spontaneous Urticaria Market Size in the 7MM was ~USD 2,200 Million in 2023 and is projected to increase during the forecast period (2024-2034). DelveInsight Business Research LLP's comprehensive report on the Chronic Spontaneous Urticaria Market offers an in-depth analysis of emerging therapies, evolving trends, and the #competitivelandscape. 📊✨ The leading #CSUCompanies such as Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United Biopharma, GSK, Allakos Inc, Eli Lilly and Company and others. Stay ahead in the dynamic world of healthcare by exploring the insights shaping the #CSUMarket. 📖 Read the full report now and transform your understanding @ https://lnkd.in/dtbbHr42 #ChronicSpontaneousUrticaria #CSUMarket #DelveInsight #HealthcareInsights #MarketResearch #BiopharmaInnovation

Thoughts on this? >> Sanofi inks deal with I-Mab; Wave discloses $175M offering on heels of DMD data >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing

What are biologics and biosimilars, and how is Teva shaping the future in this field? 💊 Biologics: Advanced medicines derived from living cells or organisms, offering new possibilities for patient care. 💊 Biosimilars: Biological medicines that closely resemble already approved biologics, providing more affordable and accessible treatment options. As a global leader in pharmaceuticals and as an integral part of its Pivot to Growth strategy, Teva is making a commitment to the emerging biosimilar market. Dive deeper into Teva's pioneering work: https://lnkd.in/d5uc5fSX #GlobalBiosimilarsWeek #DrugDevelopment #Biosimilars

Pegfilgrastim Biosimilars Global Market Report 2024 . The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to increase in cancer prevalence, government initiatives, increased healthcare expenditure, increase in biopharmaceutical R&D expenditure, low cost of biosimilars, and high penetration of the biosimilar drugs. . The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. . Read More @ https://lnkd.in/e3CwArTv . #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Great summary of the Gross-to-Net trend at big pharma.

Weren’t you able to tune into our CMC panel? Discover how industry leaders from top pharma and biotech companies navigate the complexities of CMC, focusing on strategies for early-stage de-risking, effective CMO selection, and leveraging AI to streamline processes.#Pharma #Biotech #DrugDevelopment #CMC #Pharmaceuticals

Many drugs have multiple indications, which may offer commercial opportunities but also pose strategic and operational challenges, such as varying levels of investment, regulatory hurdles, and resource allocation. Are you an emerging biopharma company with a multi-indication product? In this case study, a mid-size biopharmaceutical (EBP) focusing on #oncology drug partnered with IQVIA, which provided support by assessing and prioritizing a single indication for market approval. Discover how IQVIA implemented effective approaches to complete the analysis within a shorter timeframe while also delivering critical insights. Access the case study here: https://bit.ly/40x7noq #CRO #OncologyTrial

Thoughts on this? >> Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical